Key result
Administering cells or pharmacological agents during hypothermic machine perfusion may improve renal graft function in kidney transplantation.
Why the study?
Does administering cells or pharmacological agents during hypothermic machine perfusion improve graft function in kidney transplantation?
Does administering cells or pharmacological agents during hypothermic machine perfusion improve graft function in kidney transplantation?
This commentary highlights the potential of administering cells or pharmacological agents during hypothermic machine perfusion to improve renal graft function.
In Brief Ischemia reperfusion injury is an increasingly harmful situation in kidney transplantation. Hypothermic perfusion of renal grafts from deceased donors is implemented at many centers. This commentary addresses the possibilities of improving graft function by administering cells or pharmacological agents through renal perfusion, as shown by Hamaoui et al in this issue.
No takes yet. Share an insight, caveat, or question.
Bente Jespersen (2016) studied this question. Administering cells or pharmacological agents during hypothermic machine perfusion may improve renal graft function in kidney transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: